Pathways to Breast Cancer Recurrence

Ahmad, Aamir

doi:10.1155/2013/290568

Cited by 98 publications

(110 citation statements)

References 187 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Although the employment of screening programs and the development of new therapeutics for breast cancer have significantly reduced mortality rates in the Western world, tumour resistance to these therapeutics is a growing problem (Ahmad 2013).…”

Section: Introductionmentioning

confidence: 99%

The effect of 1:2 Ag(I) thiocyanate complexes in MCF-7 breast cancer cells

et al. 2015

View full text Add to dashboard Cite

There is much interest currently in the design of metal compounds as drugs and various metal compounds are already in clinical use. These include gold(I) compounds such as auranofin and the anti-cancer platinum(II) complex, cisplatin. Bis-chelated gold(I) phosphine complexes have also shown great potential as anticancer agents, however, their efficacy has been limited by their high toxicity. In this study, silver(I) thiocyanate compounds linked to four specific ligands, were synthesized and characterized. These silver-phosphine adducts included [AgSCN{P(4-MeC6H4)3}2]2 (1); [AgSCN{P(4-ClC6H4)3}2]2 (2); [AgSCN{P(4-MeOC6H4)3}2]2 (3); [AgSCN(PPh3)2]2 (4). The compounds were found to be toxic to MCF-7 breast cancer cells while the ligands on their own were not toxic. Our findings further indicate that the silver(I) phosphine compounds induce apoptotic cell death in these breast cancer cells. In addition, the compounds were not toxic to nonmalignant fibroblast cells at the IC50 concentrations. This is an indication that the compounds show selectivity towards the cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of 1:2 Ag(I) thiocyanate complexes in MCF-7 breast cancer cells

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, drug resistance still remains a puzzling problem which has been an obstacle to the clinical treatment of breast cancer [4]. Research showed that 30% of the patients with early stage breast cancer relapsed and developed metastatic disease, at least a quarter of which were the results of resistance to the therapeutic agents [5].…”

Section: Introductionmentioning

confidence: 99%

Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology

Wang

Huang

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Although a few screening tools exist to determine who is at risk of recurrence, overall the molecular dynamics are still poorly understood [6]. It is also well described in the literature that angiogenesis plays an important role in hormonal resistance and further tumor recurrence in cases of previously treated breast carcinoma [7] [8] [9] [10] [11].…”

mentioning

confidence: 99%

Role of Anti Angiogenic Therapy in Prevention of Recurrence in Hormonal Positive Breast Cancer: A Secondary Prevention Strategy and Method of Therapy

Nezami¹,

Garner²

2017

JCT

View full text Add to dashboard Cite

Existing literature supports the role of signaling protein vascular endothelial growth factor (VEGF) in tumor growth and metastasis and furthers its involvement in recurrence. In both experimental and clinical studies, VEGF has been shown to be a significant factor involved for aberrant blood vessel growth, and in fact is the target of several classes of antineoplastic drugs [1] [2] [3] [4]. That said, the current standard of care for estrogen receptor positive breast cancer (although improved over the last decade), has not provided a "meaningful preventive shift" since the discovery of angiogenesis and its role in induction of recurrence. In this article, we discuss an anti angiogenic therapy implementing natural compounds to inhibit the production of VEGF. We applied our preclinical data to justify the predicted effect on VEGF. We used liquid biopsy to monitor patients response to therapy as a surrogate for recurrence. We hypothesize that by inhibition of angiogenesis through this protocol, we are able to positively impact tumor recurrence. It is our experience that patients in our sample even with high recurrence scores (based on Oncotype Dx testing) had a major reduction in recurrence when estrogen blockers were combined with this protocol. We also propose longitudinal studies to compare outcomes with combinational therapies with estrogen blockers in highly expected to recur disease.

show abstract

Pathways to Breast Cancer Recurrence

Cited by 98 publications

References 187 publications

The effect of 1:2 Ag(I) thiocyanate complexes in MCF-7 breast cancer cells

The effect of 1:2 Ag(I) thiocyanate complexes in MCF-7 breast cancer cells

Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology

Role of Anti Angiogenic Therapy in Prevention of Recurrence in Hormonal Positive Breast Cancer: A Secondary Prevention Strategy and Method of Therapy

Contact Info

Product

Resources

About